Celgene Corporation (CELG) - Financial and Strategic SWOT Analysis Review

Date: October 4, 2016
Pages: 79
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: CB9378AE000EN
Leaflet:

Download PDF Leaflet

Celgene Corporation (CELG) - Financial and Strategic SWOT Analysis Review
Celgene Corporation (CELG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Celgene Corporation (Celgene) is an integrated global biopharmaceutical company. It carries out the research, development, manufacture and marketing of novel therapies to treat cancer and immune-inflammatory related diseases through gene and protein regulation. Its product portfolio includes Vidaza for the treatment of myelodysplastic syndromes (MDS), Revlimid, Pomalyst and Thalomid for the treatment of multiple myeloma, Abraxane for cancer, Otezla active psoriatic arthritis, and Istodax for cutaneous T-cell lymphoma (CTCL) and eripheral T-cell lymphoma (PTCL). The company also has several products in various stages of development for the treatment of hematological and solid tumor cancers. Celgene is headquartered in Summit, New Jersey, the US.

Celgene Corporation Key Recent Developments

Sep 07, 2016: Sutro Marks Important Progress - Receives Two Milestone Payments from Celgene
Jul 28, 2016: Celgene Reports Second Quarter 2016 Operating and Financial Results
Jun 09, 2016: Celgene Announces Presentations of Investigational Studies in Blood Cancers at EHA 2016
Jun 07, 2016: Study Reveals Racial Disparities in Multiple Myeloma Treatment Patterns
May 24, 2016: COTA Increases Cross-Industry Support With the Addition of Celgene, Foundation Medicine HealthScape Advisors and Novartis as Strategic Investors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Celgene Corporation - Key Facts
Celgene Corporation - Key Employees
Celgene Corporation - Key Employee Biographies
Celgene Corporation - Major Products and Services
Celgene Corporation - Pharmaceutical Pipeline Products Data
Celgene Corporation, Pipeline Products by Therapy Area
Celgene Corporation, Pipeline Products by Development Phase
Celgene Corporation - History
Celgene Corporation - Company Statement
Celgene Corporation - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Celgene Corporation - Business Description
Celgene Corporation - Corporate Strategy
Celgene Corporation - SWOT Analysis
SWOT Analysis - Overview
Celgene Corporation - Strengths
Strength - Increased Product Sales Drives Revenue
Strength - Focused Research and Development Activities
Strength - Strong Presence - Multiple Myeloma Market
Celgene Corporation - Weaknesses
Weakness - Imnovid - Birth Defects Risks
Weakness - Decline in Vidaza and Thalomid
Celgene Corporation - Opportunities
Opportunity - Product Approvals and Launches
Opportunity - Late Stage Development Pipeline
Opportunity - Business Initiatives
Opportunity - Strategic Partnerships
Opportunity - Strategic Acquisitions
Celgene Corporation - Threats
Threat - Litigations and Legal Issues
Threat - Highly Competitive Industry
Threat - Stringent Government Regulations
Celgene Corporation - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Celgene Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Celgene Corporation, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Celgene Corporation, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Sep 07, 2016: Sutro Marks Important Progress - Receives Two Milestone Payments from Celgene
Jul 28, 2016: Celgene Reports Second Quarter 2016 Operating and Financial Results
Jun 09, 2016: Celgene Announces Presentations of Investigational Studies in Blood Cancers at EHA 2016
Jun 07, 2016: Study Reveals Racial Disparities in Multiple Myeloma Treatment Patterns
May 24, 2016: COTA Increases Cross-Industry Support With the Addition of Celgene, Foundation Medicine HealthScape Advisors and Novartis as Strategic Investors
May 18, 2016: Celgene Announces Presentations of Investigational Studies in Solid Tumor and Blood Cancers at ASCO 2016
Apr 28, 2016: Celgene Reports First Quarter 2016 Operating and Financial Results
Feb 11, 2016: Celgene Elects Mark Alles and Jacqualyn Fouse PhD to its Board of Directors
Feb 10, 2016: Celgene Expands Relationship with Medidata in Enterprise Clinical Trial Technology
Jan 28, 2016: Celgene Reports Fourth Quarter and Full Year 2015 Operating and Financial Results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Celgene Corporation, Key Facts
Celgene Corporation, Key Employees
Celgene Corporation, Key Employee Biographies
Celgene Corporation, Major Products and Services
Celgene Corporation, Number of Pipeline Products by Therapy Area
Celgene Corporation, Number of Pipeline Products by Development Stage
Celgene Corporation, Pipeline Products By Therapy Area and Development Phase
Celgene Corporation, History
Celgene Corporation, Other Locations
Celgene Corporation, Subsidiaries
Celgene Corporation, Key Competitors
Celgene Corporation, Ratios based on current share price
Celgene Corporation, Annual Ratios
Celgene Corporation, Interim Ratios
Celgene Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Celgene Corporation, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Celgene Corporation, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Celgene Corporation, Pipeline Products by Therapy Area
Celgene Corporation, Pipeline Products by Development Phase
Celgene Corporation, Performance Chart (2011 - 2015)
Celgene Corporation, Ratio Charts
Celgene Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Celgene Corporation, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016

COMPANIES MENTIONED

Vical Incorporated
Takeda Pharmaceutical Company Limited
Quanta BioDesign, Ltd.
Onconova Therapeutics, Inc.
Novartis AG
NewLink Genetics Corporation
Merck & Co., Inc.
Johnson & Johnson
Ignyta, Inc.
Eisai Co., Ltd.
CTI BioPharma Corp.
Cellceutix Corporation
Bristol-Myers Squibb Company
AstraZeneca Plc
Amgen Inc.
Abbott Laboratories
Skip to top


Ask Your Question

Celgene Corporation (CELG) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: